Intravitreal Dexamethasone Implant Versus Intravitreal Ranibizumab Injection for Treatment of Macular Edema Secondary to Retinal Vein Occlusion: a Prospective, Randomized Trial.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042682

Enrollment

Unknown

Registered

2021-01-26

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular edema

Interventions

Group 1:Lucentis

Group 2:Lucentis and Ozudex

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with central retinal vein occlusion or branch retinal vein occlusion complicated with macular edema were enrolled as follows: Aged 18 years; 20/40 vision; Macular central retinal thickness (CRT) OCT 250um; OCT confirmed macular edema; The FA assessment identified macular edema as the cause of vision loss due to non-ischemic CRVO or BRVO or ischemic retinal photocoagulation therapy.

Exclusion criteria

Exclusion criteria: Neovascularization of the anterior macular membrane eye infection glaucoma and high intraocular pressure (IOP;21mmHg); Diabetic retinopathy; A history of high IOP due to hormones; Vitreous injection of steroids or other drugs within 3 months; Immunosuppressants, immunomodulators, antimetabolites, etc..

Design outcomes

Primary

Measure	Time frame
Best corrected vision acurity;central retinal thickness;Cytokines;	—

Countries

China

Contacts

Public ContactXiubin Ma

Shandong First Medical University affiliated Qingdao Eye Hospital

maxiubin2005@126.com+86 15864254696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026